TBPH:NSD-Theravance Biopharma Inc. (USD)

EQUITY | Biotechnology | NASDAQ Global Market

Last Closing

USD 9.39

Change

-0.19 (-1.98)%

Market Cap

USD 1.50B

Volume

0.30M

Analyst Target

USD 31.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Theravance Biopharma Inc is engaged in discovery, research, development and commercialization of human therapeutics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 110.51B
MRNA Moderna Inc

N/A

USD 57.87B
ARGX argenx NV ADR

N/A

USD 22.80B
BNTX BioNTech SE

N/A

USD 22.68B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 19.33B
GMAB Genmab AS

N/A

USD 18.15B
BGNE BeiGene Ltd

N/A

USD 17.74B
RPRX Royalty Pharma Plc

N/A

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.32B

ETFs Containing TBPH

SDIP:LSE Global X SuperDividend UC.. 1.47 % 0.00 %

N/A

USD 0.10B
SDIU:LSE Global X SuperDividend UC.. 1.47 % 0.00 %

N/A

USD 0.24M
SDIV:LSE Global X SuperDividend UC.. 1.47 % 0.00 %

N/A

USD 0.10B
SDIV Global X SuperDividend ET.. 0.00 % 0.59 %

N/A

USD 0.80B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.46% 39% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.46% 39% F 27% F
Trailing 12 Months  
Capital Gain -15.48% 55% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.48% 55% F 34% F
Trailing 5 Years  
Capital Gain -54.51% 55% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.51% 55% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -12.93% 43% F 24% F
Dividend Return -12.93% 43% F 23% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.98% 89% A- 65% D
Risk Adjusted Return -46.21% 34% F 21% F
Market Capitalization 1.50B 69% C- 61% D-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 2.19 58% 45%
Price / Cash Flow Ratio -16.40 90% 86%
Price/Free Cash Flow Ratio -9.69 87% 84%
Management Effectiveness  
Return on Equity -16.86% 90% 46%
Return on Invested Capital -18.09% 80% 35%
Return on Assets -6.73% 93% 38%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector